LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

CytomX Therapeutics Inc

Затворен

СекторЗдравеопазване

2.26 -1.74

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.2

Максимум

2.43

Ключови измерители

By Trading Economics

Приходи

4.6M

24M

Продажби

13M

51M

P/E

Средно за сектора

4.5

50.291

EPS

0.27

Марж на печалбата

46.203

Служители

119

EBITDA

4.9M

23M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+94.81% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

193M

365M

Предишно отваряне

4

Предишно затваряне

2.26

Настроения в новините

By Acuity

50%

50%

162 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

CytomX Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.06.2025 г., 20:51 ч. UTC

Печалби

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 20:48 ч. UTC

Пазарно говорене

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27.06.2025 г., 19:31 ч. UTC

Пазарно говорене

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27.06.2025 г., 19:19 ч. UTC

Пазарно говорене

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27.06.2025 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27.06.2025 г., 18:39 ч. UTC

Пазарно говорене
Печалби

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27.06.2025 г., 18:18 ч. UTC

Пазарно говорене

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27.06.2025 г., 18:16 ч. UTC

Пазарно говорене

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27.06.2025 г., 17:16 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27.06.2025 г., 17:08 ч. UTC

Печалби

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27.06.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27.06.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

27.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

27.06.2025 г., 15:59 ч. UTC

Пазарно говорене

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27.06.2025 г., 15:56 ч. UTC

Пазарно говорене

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

CytomX Therapeutics Inc Прогноза

Ценова цел

By TipRanks

94.81% нагоре

12-месечна прогноза

Среден 4.5 USD  94.81%

Висок 5 USD

Нисък 3.5 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за CytomX Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.7658 / N/AПодкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

162 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.